Abbott RealTime HCV Genotype II assay receives FDA approval FDA approves first genotyping check for patients with hepatitis C virus The U.S Read more . Meals and Drug Administration today authorized a check that identifies the genotype of hepatitis C virus that a patient is carrying. The Abbott RealTime HCV Genotype II, which can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5,using a sample of an contaminated patient's blood plasma or serum, will aid health care specialists in determining the correct approach to treatment. Because the numerous HCV genotypes respond in a different way to available drug therapies, knowing the type of HCV one is infected with can lead to better patient outcomes. Tests like this one can help doctors gain a knowledge of a patient's HCV status," stated Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in FDA's Center for Radiological and Devices Health.